Incyte stock plummets following disappointing clinical study results

Incyte Corp. ’s stock price plunged nearly 20 percent Friday after the Wilmington biotechnology company announced disappointing late-stage study results for an experimental cancer therapy. The results from a phase-III clinical study, testing Incyte’s new drug candidate epacadostat with Merck& Co. Inc. ’s immunotherapy drug Keytruda, found the combination therapy did not improve progression-free survival in patients with metastatic melanoma, a type of skin cancer. Incyte and Merck said, at…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news